Publications by authors named "Ali Murat Tatli"

Claim this Profile
R
Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis From the Turkish Oncology Group.
Tuğba Akın Telli, Ali Murat Tatlı, Özkan Alan, Gülsema Yıldıran Keskin, Nuri Karadurmuş

Clin Lung Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive value of tumor marker index for pathological complete response following neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
Selami Bayram, Mustafa Serkan Alemdar, Ali Murat Tatli, Mustafa Ozdogan

World J Surg Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Oncological Outcomes for Locally Advanced Rectal Cancer Patients with Pathological Complete Response After Neoadjuvant Chemoradiotherapy: A Turkish Oncology Group Study.
Mukremin Uysal, Sezer Saglam, İsmail Beypınar, Esra Kaytan Saglam, Elkhan Mammadov, Ali Murat Tatli

Cancer Invest· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avelumab maintenance in patients with metastatic urothelial carcinoma in a real-life expanded-access program.
Deniz Tural, Oğuzcan Özkan, Eda Eylemer Mocan, Caner Kapar, Sendag Yaslikaya

Future Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Kalkan et al. Efficacy of Immunotherapy Versus Chemotherapy in Advanced Pleural Mesothelioma: A Turkish Oncology Group (TOG) Study. 2025, , 638.
Ziya Kalkan, Senar Ebinc, Murat Arcagok, Ahmet Bilici, Ozcan Yildiz, Ali Murat Tatli

Medicina (Kaunas)· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Failure patterns and the influence of the TNM staging systems on prognosis in limited disease small cell lung Cancer (SCLC): the Turkish Oncology Group (TOG) study.
Şefika Arzu Ergen, Fazilet Öner Dinçbaş, Evrim Metcalfe, Şule Karabulut Gül, Serap Akyürek

Clin Transl Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of Pathologic Complete Response and Its Prognostic Value in Early Breast Cancer: A Real-World Cohort Study.
Selami Bayram, Ali Murat Tatli, Muharrem Okan Cakir, Mustafa Ozdogan

Curr Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Role of Inflammatory and Nutritional Indices in NSCLC Patients Treated with Immune Checkpoint Inhibitors: Retrospective, Multicenter, Turkish Oncology Group Study of Overall and Elderly Populations.
Ozkan Alan, Tugba Akın Telli, Sinem Akbas, Selver Isik, Eyyüb Çavdar, Ali Murat Tatli

Medicina (Kaunas)· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival Outcomes in Metastatic Germ Cell Tumors: A Multicenter Study from Turkey.
Gul Sema Yildiran Keskin, Ozge Yetginoglu, Sertac Vurgun, Evrican Zin Guzel, Fariz Emrah Ozkan, Ali Murat Tatli

Medicina (Kaunas)· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Immunotherapy Versus Chemotherapy in Advanced Pleural Mesothelioma: A Turkish Oncology Group (TOG) Study.
Ziya Kalkan, Senar Ebinc, Murat Arcagok, Ahmet Bilici, Ozcan Yildiz, Ali Murat Tatli

Medicina (Kaunas)· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Standard Neoadjuvant Therapy and Total Neoadjuvant Therapy in Terms of Effectiveness in Patients Diagnosed with Locally Advanced Rectal Cancer.
Ayberk Bayramgil, Ahmet Bilici, Ali Murat Tatlı, Seda Kahraman, Yunus Emre Altintas

Medicina (Kaunas)· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing Treatment Decisions for Advanced Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations: A Reinforcement Learning Approach.
Hakan Şat Bozcuk, Leyla Sert, Muhammet Ali Kaplan, Ali Murat Tatlı, Mustafa Karaca

Cancers (Basel)· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of body mass index on the progression-free survival of CDK 4/6 inhibitors in metastatic breast cancer patients.
Dilek Çağlayan, Mehmet Zahid Koçak, Çağlayan Geredeli, Muhammed Mustafa Atcı, Ali Murat Tatlı

Future Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential Use of Sorafenib and Regorafenib in Hepatocellular Cancer Recurrence After Liver Transplantation: Treatment Strategies and Outcomes.
Mehmet Fatih Ozbay, Hakan Harputluoglu, Mustafa Karaca, Omer Tekin, Mehmet Ali Nahit Şendur

Cancers (Basel)· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy.
Saadettin Kilickap, Akin Ozturk, Nuri Karadurmus, Taner Korkmaz, Perran Fulden Yumuk, Ali Murat Tatli

Medicine (Baltimore)· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic significance of tumor budding, desmoplastic reaction, and lymphocytic infiltration in patients with gastric adenocarcinoma.
Aysen Yavuz, Kubra Simsek, Anil Alpsoy, Busra Altunay, Elif Ocak Gedik, Ali Murat Tatli

World J Gastrointest Pathophysiol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases.
Seda Kahraman, Serdar Karakaya, Muhammed Ali Kaplan, Sema Sezgin Goksu, Akin Ozturk, Ali Murat Tatli

Sci Rep· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is there any prognostic significance in pleural involvement and/or effusion in patients with ALK-positive NSCLC?
Gürkan Güner, Burak Yasin Aktaş, Fatma Buğdaycı Başal, Ahmet Demirkazık, Pınar Gürsoy

J Cancer Res Clin Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group.
Çağlar Ünal, Abdulmunir Azizy, Senem Karabulut, Didem Taştekin, Arif Akyıldız

Oncologist· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of concomitant proton pump inhibitor use on survival outcomes of Nivolumab-treated renal cell carcinoma patients: a multicenter study.
Muzaffer Uğraklı, Mehmet Zahid Koçak, Gülhan Dinç, Tuğrul Burak Genç, Melek Çağlayan

J Cancer Res Clin Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the Efficacy and Safety of 3 Months of CAPOX Followed by 3 Months of Capecitabine and 6 Months of CAPOX/FOLFOX in the Adjuvant Treatment of Low-Risk Stage III Colon Cancer Treated Surgically.
Murat Bardakci, Derya Demirtas Esmer, Emre Hafizoglu, Sendag Yaslikaya, Tugrul Burak Genc, Ali Murat Tatli

Oncology· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of using adjuvant aromatase inhibitors on cognitive functions in postmenopausal women with hormone receptor-positive breast cancer.
Rukiye Guler Ilhan, Yusuf Ilhan, Sema Sezgin Goksu, Ali Murat Tatli, Hasan Senol Coskun

J Cancer Res Ther· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of concomitant use of proton pump inhibitors with CDK 4/6 inhibitors on survival in metastatic breast cancer.
Dilek Çağlayan, Mehmet Zahid Koçak, Çağlayan Geredeli, Ali Murat Tatlı, Sema Sezgin Göksu

Eur J Clin Pharmacol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group.
Mustafa Gürbüz, Saadettin Kiliçkap, Ahmet Bilici, Nuri Karadurmuş, Ahmet Sezer, Ali Murat Tatli

Medicine (Baltimore)· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lung Cancer in Turkey.
Ayten Kayı Cangır, Perran Fulden Yumuk, Serpil Dizbay Sak, Serap Akyürek, Yeşim Eralp

J Thorac Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis